Comparative Effectiveness of Licensed Influenza Vaccines in Preventing Influenza-related Medical Encounters and Hospitalizations in the 2022-2023 Influenza Season Among Adults ≥65 Years of Age.
Jennifer H KuEmily RayensLina S SyLei QianBradley K AckersonYi LuoJulia E TubertGina S LeePunam P ModhaYoonyoung ParkTianyu SunEvan J AndersonHung Fu TsengPublished in: Clinical infectious diseases : an official publication of the Infectious Diseases Society of America (2024)
Compared to the SD egg-based vaccine, HD and adjuvanted vaccines conferred additional protection against influenza-related outcomes in the 2022-2023 season in adults ≥65 years. Our results provide real-world evidence of the comparative effectiveness of currently licensed vaccines.